US approves Gilead's twice-yearly injection to prevent HIV / Photo: JUSTIN SULLIVAN - GETTY IMAGES NORTH AMERICA/AFP
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," said Daniel O'Day, Gilead's chairman and chief executive officer, in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown in clinical trials to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
But optimism may be tempered by the drug's expected eye-watering price tag.
While the company has not disclosed specifics, analysts estimate the US launch price could be as high as $25,000 per year.
Activists are calling for the price to be slashed to $25 per person annually to help end the HIV pandemic.
The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both overseas and within the United States.
W.Mansour--SF-PST
